IGMS Stock Overview
A clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
IGM Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.27 |
52 Week High | US$17.70 |
52 Week Low | US$3.81 |
Beta | 0.19 |
11 Month Change | -20.77% |
3 Month Change | 0.54% |
1 Year Change | 23.60% |
33 Year Change | -87.16% |
5 Year Change | n/a |
Change since IPO | -61.85% |
Recent News & Updates
Recent updates
IGM Biosciences: Unlikely To Move The Needle Again In 2024
May 12Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Feb 08IGM Biosciences reports quick assets and provides business updates
Jan 13Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares
Dec 18IGM Bio prices upsized $200M public offering
Dec 09IGM Biosciences proposes public offering
Dec 07Shareholder Returns
IGMS | US Biotechs | US Market | |
---|---|---|---|
7D | 2.3% | 2.7% | 4.0% |
1Y | 23.6% | 15.4% | 24.9% |
Return vs Industry: IGMS exceeded the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: IGMS exceeded the US Market which returned 21.7% over the past year.
Price Volatility
IGMS volatility | |
---|---|
IGMS Average Weekly Movement | 19.3% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IGMS's share price has been volatile over the past 3 months.
Volatility Over Time: IGMS's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 216 | Fred Schwarzer | igmbio.com |
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
IGM Biosciences, Inc. Fundamentals Summary
IGMS fundamental statistics | |
---|---|
Market cap | US$517.26m |
Earnings (TTM) | -US$220.40m |
Revenue (TTM) | US$2.91m |
188.9x
P/S Ratio-2.5x
P/E RatioIs IGMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IGMS income statement (TTM) | |
---|---|
Revenue | US$2.91m |
Cost of Revenue | US$213.79m |
Gross Profit | -US$210.88m |
Other Expenses | US$9.52m |
Earnings | -US$220.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.72 |
Gross Margin | -7,244.21% |
Net Profit Margin | -7,571.35% |
Debt/Equity Ratio | 0% |
How did IGMS perform over the long term?
See historical performance and comparison